Proteomic-Based Biosignatures in Breast Cancer Classification and Prediction of Therapeutic Response
Figure 3
CK19 expressions detected by LC-MS/MS and immunohistochemical (IHC) staining. Elevated CK19 expressions found in HER+ tumor group by LC-MS/MS and confirmed by IHC in most of the frozen HER2+ tumors. (a) Normalized spectrum count of CK19 detected in 39 breast cancer tissues. (b) Immunohistochemical staining of CK19 in a HER2+ frozen tumor (power 200x). (c) Immunohistochemical staining of CK19 in a TNBC frozen tumor (power 200x).
